The Food and Drug Administration (FDA) has approved Wynzora® Cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%; MC2 Therapeutics) for the treatment of plaque psoriasis in patients ...

Betamethasone is an inflammation-reducing corticosteroid that helps treat a range of skin conditions. Learn about the types, uses, and side effects of this medication here, as well as the warnings ...

Wynzora ® Cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%) is now available for the topical treatment of plaque psoriasis in adults 18 years of age and older.

Psoriasis patients treated with a cream formulation of calcipotriene and betamethasone dipropionate developed with PAD technology showed significant improvement over those treated with a ...

A novel formulation of calcipotriene (CAL), betamethasone dipropionate (BDP) cream was found to be more effective, provide superior quality of life, and safe in patients with psoriasis, compared ...